间变性淋巴瘤激酶
受体酪氨酸激酶
配体(生物化学)
受体蛋白酪氨酸激酶
癌症研究
化学
酪氨酸激酶
神经母细胞瘤
激酶
受体
细胞生物学
生物
生物化学
遗传学
医学
内科学
恶性胸腔积液
胸腔积液
细胞培养
作者
Tongqing Li,Steven E. Stayrook,Yuko Tsutsui,Jianan Zhang,Yueyue Wang,Hengyi Li,Andrew Proffitt,S.G. Krimmer,Mansoor Ahmed,Olivia Belliveau,Ian X. Walker,Krishna C. Mudumbi,Yoshihisa Suzuki,Irit Lax,Diego Alvarado,Mark A. Lemmon,Joseph Schlessinger,Daryl E. Klein
出处
期刊:Nature
[Nature Portfolio]
日期:2021-11-24
卷期号:600 (7887): 148-152
被引量:33
标识
DOI:10.1038/s41586-021-04141-7
摘要
The proto-oncogene ALK encodes anaplastic lymphoma kinase, a receptor tyrosine kinase that is expressed primarily in the developing nervous system. After development, ALK activity is associated with learning and memory1 and controls energy expenditure, and inhibition of ALK can prevent diet-induced obesity2. Aberrant ALK signalling causes numerous cancers3. In particular, full-length ALK is an important driver in paediatric neuroblastoma4,5, in which it is either mutated6 or activated by ligand7. Here we report crystal structures of the extracellular glycine-rich domain (GRD) of ALK, which regulates receptor activity by binding to activating peptides8,9. Fusing the ALK GRD to its ligand enabled us to capture a dimeric receptor complex that reveals how ALK responds to its regulatory ligands. We show that repetitive glycines in the GRD form rigid helices that separate the major ligand-binding site from a distal polyglycine extension loop (PXL) that mediates ALK dimerization. The PXL of one receptor acts as a sensor for the complex by interacting with a ligand-bound second receptor. ALK activation can be abolished through PXL mutation or with PXL-targeting antibodies. Together, these results explain how ALK uses its atypical architecture for its regulation, and suggest new therapeutic opportunities for ALK-expressing cancers such as paediatric neuroblastoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI